Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Akcea Therapeutics, Inc.    AKCA

AKCEA THERAPEUTICS, INC.

(AKCA)
  Report
 SummaryQuotesChartsNewsRatingsCompanyFinancials 
Financials (USD)
Sales 2018 64,9 M - -
Net income 2018 -226 M - -
Net cash position 2018 248 M - -
P/E ratio 2018 -10,5x
Yield 2018 -
Sales 2019 489 M - -
Net income 2019 40,8 M - -
Net cash position 2019 448 M - -
P/E ratio 2019 59,2x
Yield 2019 -
Capitalization 1 849 M 1 849 M -
EV / Sales 2018 37,6x
EV / Sales 2019 2,34x
Nbr of Employees 294
Free-Float 17,2%
More Financials
Company
Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company's volanesorsen drug... 
Sector
Pharmaceuticals
Calendar
-
More about the company
Notations Surperformance© of Akcea Therapeutics, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about AKCEA THERAPEUTICS, INC.
11/10IONIS PHARMACEUTICALS : Akcea Therapeutics - WAYLIVRA, the first and only therap..
AQ
11/09IONIS PHARMACEUTICALS : and Akcea Recognize FCS Awareness Day with Global Commun..
AQ
11/04IONIS PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
11/04Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study ..
AQ
11/02IONIS PHARMACEUTICALS : and Akcea win prestigious Prix Galien Award for TEGSEDI ..
AQ
10/13IONIS PHARMACEUTICALS : completes acquisition of Akcea Therapeutics
AQ
10/13AKCEA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Notice of..
AQ
10/13IONIS PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, ..
AQ
10/12AKCEA THERAPEUTICS : Ionis Pharmaceuticals completes acquisition of Akcea Therap..
PR
09/18AKCEA THERAPEUTICS : WAYLIVRA▼® (volanesorsen), the First and Only Therapy..
BU
09/11WeissLaw LLP Reminds AKCA and AIMT Shareholders About Its Ongoing Investigati..
PR
09/05KASKELA LAW LLC : Announces Stockholder Investigation of Akcea Therapeutics, Inc..
PR
09/04AKCEA INVESTOR ALERT BY THE FORMER A : Kahn Swick & Foti, LLC Investigates Adequ..
BU
09/01Monteverde & Associates PC Announces an Investigation of Akcea Therapeutics, ..
PR
08/31AKCEA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Amendment..
AQ
More news
News in other languages on AKCEA THERAPEUTICS, INC.
2019AKCEA THERAPEUTICS INC : Veröffentlichung des Jahresergebnisses
2019AKCEA THERAPEUTICS INC : publication des résultats annuels
More news
Chart AKCEA THERAPEUTICS, INC.
Duration : Period :
Akcea Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers
NameTitle
Damien McDevitt Chief Executive Officer
Brett P. Monia President & Director
Alex G. Howarth Chief Operating Officer
Michael Dennis Price Chief Financial Officer & Executive Vice President
William T. Andrews Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
AKCEA THERAPEUTICS, INC.7.26%1 849
JOHNSON & JOHNSON-1.50%378 244
ROCHE HOLDING AG-3.47%285 939
NOVARTIS AG-11.58%203 854
PFIZER INC.-1.59%203 048
MERCK & CO., INC.-11.97%202 555